We are live on ! Find out more
TECP

Trails Edge Capital Partners Portfolio holdings

AUM $630M
This Fund
S&P 500
This Quarter Est. Return
+17.35%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$437M
AUM Growth
+$31.8M
Cap. Flow
+$10.1M
Cap. Flow %
2.32%
Top 10 Hldgs %
62.79%
Holding
35
New
12
Increased
4
Reduced
7
Closed
8

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$28.4M
2
RVMD icon
Revolution Medicines
RVMD
+$24.7M
3
CYTK icon
Cytokinetics
CYTK
+$19.1M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$15.2M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$11.3M

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$37.9M
2
TYRA icon
Tyra Biosciences
TYRA
+$18.4M
3
FOLD
Amicus Therapeutics
FOLD
+$14.9M
4
APGE icon
Apogee Therapeutics
APGE
+$14.5M
5
DFTX
Definium Therapeutics
DFTX
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.64B
$38.5M 8.82%
662,470
-75,000
-10% -$4.07M
DFTX
2
Definium Therapeutics
DFTX
$5.73B
$32.9M 7.53%
1,738,110
-830,000
-32% -$14.1M
LBRX
3
LB Pharmaceuticals
LBRX
$1.54B
$32.5M 7.45%
1,319,362
-76,246
-5% -$1.76M
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.14B
$30.8M 7.05%
333,312
+301,450
+946% +$28.4M
NRIX icon
5
Nurix Therapeutics
NRIX
$2.81B
$27M 6.19%
1,743,220
– –
XENE icon
6
Xenon Pharmaceuticals
XENE
$6.03B
$25.6M 5.86%
440,000
-157,092
-26% -$7.24M
RVMD icon
7
Revolution Medicines
RVMD
$43.7B
$23.8M 5.46%
+245,000
New +$24.7M
RCUS icon
8
Arcus Biosciences
RCUS
$3.75B
$22.6M 5.19%
1,047,935
+131,622
+14% +$2.84M
IMCR icon
9
Immunocore
IMCR
$1.74B
$20.6M 4.71%
682,597
– –
CYTK icon
10
Cytokinetics
CYTK
$10.3B
$19.8M 4.53%
+300,000
New +$19.1M
SNDX icon
11
Syndax Pharmaceuticals
SNDX
$1.77B
$16.4M 3.76%
+701,821
New +$15.2M
NGNE icon
12
Neurogene
NGNE
$723M
$15.8M 3.62%
782,787
-2,213
-0.3% -$42.9K
IVA
13
Inventiva
IVA
$1.09B
$14.8M 3.38%
2,657,997
– –
IKT icon
14
Inhibikase Therapeutics
IKT
$378M
$13.5M 3.1%
8,057,345
+1,879,221
+30% +$3.34M
FDMT icon
15
4D Molecular Therapeutics
FDMT
$637M
$12.1M 2.78%
+1,302,917
New +$11.3M
XENE icon
16
PUT
Xenon Pharmaceuticals
XENE
$6.03B
$11.6M 2.66%
+200,000
New +$9.22M
XFOR icon
17
X4 Pharmaceuticals
XFOR
$418M
$10.6M 2.43%
2,571,478
– –
IMVT icon
18
Immunovant
IMVT
$8.64B
$10.3M 2.36%
414,054
+173,889
+72% +$4.5M
DSGN icon
19
Design Therapeutics
DSGN
$928M
$9.07M 2.08%
+852,013
New +$8.62M
CAMP icon
20
CAMP4 Therapeutics
CAMP
$341M
$8.55M 1.96%
1,939,563
-44,423
-2% -$211K
NERV icon
21
Minerva Neurosciences
NERV
$219M
$8.55M 1.96%
+1,419,000
New +$8.14M
PMN icon
22
ProMIS Neurosciences
PMN
$133M
$7.08M 1.62%
+557,103
New +$8.31M
SLGL icon
23
Sol-Gel Technologies
SLGL
$277M
$6.77M 1.55%
+85,496
New +$6.17M
IPSC icon
24
Century Therapeutics
IPSC
$348M
$5.54M 1.27%
+2,449,993
New +$5.15M
VTVT icon
25
vTv Therapeutics
VTVT
$119M
$5.54M 1.27%
139,578
-91,422
-40% -$3.32M
1
2

Similar funds

SJIC
St. James Investment Company Southlake, Texas $630M AUM 12.48% 1-Year Est. Return
SFO
Stenger Family Office Naperville, Illinois $629M AUM 25.67% 1-Year Est. Return
PPC
Park Place Capital Homewood, Alabama $629M AUM 18.27% 1-Year Est. Return
ACGA
Atlanta Consulting Group Advisors Atlanta, Georgia $631M AUM 22.46% 1-Year Est. Return
FAM
Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return
MC
Machina Capital Paris, France $631M AUM 11.37% 1-Year Est. Return
GPTE
Generali Powszechne Towarzystwo Emerytalne Warsaw, Poland $631M AUM 32.98% 1-Year Est. Return
KNW
Kesler Norman & Wride Ogden, Utah $631M AUM 27.63% 1-Year Est. Return

Trails Edge Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Trails Edge Capital Partners held 35 positions worth $437M, up 7.9% from $405M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Trails Edge Capital Partners's Q1 2026 filing shows 12 new, 4 increased, 7 reduced and 8 closed positions. Its largest new stake was Revolution Medicines: 245,000 shares worth $23.8M. The largest sale was Acadia Pharmaceuticals, an estimated $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 100% a quarter earlier.

  • Trails Edge Capital Partners's largest Q1 2026 buy was Revolution Medicines: 245,000 shares worth $23.8M.
  • Trails Edge Capital Partners added most to Mirum Pharmaceuticals in Q1 2026, an estimated $28.4M increase.
  • Trails Edge Capital Partners's biggest Q1 2026 reduction was Definium Therapeutics, cutting an estimated $14.1M.
  • Trails Edge Capital Partners fully exited Acadia Pharmaceuticals in Q1 2026, selling an estimated $37.9M.
  • Trails Edge Capital Partners's ten largest holdings make up 63% of its $437M portfolio in Q1 2026.
  • Trails Edge Capital Partners opened 12 new positions and closed 8 in Q1 2026.
  • Trails Edge Capital Partners's portfolio value rose 7.9% quarter-over-quarter to $437M.

Based on Trails Edge Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.